These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32222082)

  • 21. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis.
    Hanai Y; Hamada Y; Kimura T; Matsumoto K; Takahashi Y; Fujii S; Nishizawa K; Takesue Y
    J Infect Chemother; 2021 Feb; 27(2):151-160. PubMed ID: 33376032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
    Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
    Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
    Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y
    Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
    Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
    Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections.
    Xing Y; Chen L; Feng Y; Zhou Y; Zhai Y; Lu J
    BMC Infect Dis; 2017 Dec; 17(1):798. PubMed ID: 29281997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.
    Imhof A; Schaer DJ; Schanz U; Schwarz U
    Swiss Med Wkly; 2006 Nov; 136(45-46):739-42. PubMed ID: 17183438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
    Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
    J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
    Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients.
    Allegra S; De Francia S; De Nicolò A; Cusato J; Avataneo V; Manca A; Antonucci M; D'Avolio A
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):405-412. PubMed ID: 31965553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.
    Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM
    Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
    Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
    Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
    Tang L; Yang XF; Qiao M; Zhang L; Tang XW; Qiu HY; Wu DP; Sun AN
    J Mycol Med; 2018 Jun; 28(2):379-383. PubMed ID: 29673771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].
    Qu HL; Guo DD; Xu T; Li Z; Yin J; Tian XP; Kong DQ; Zhu XM; Miao LY; Wu DP; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):202-206. PubMed ID: 29562464
    [No Abstract]   [Full Text] [Related]  

  • 40. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.